INTRODUCTION

Pancreatectomy is the total or partial resection of the pancreas and is the major treatment modality for many benign and malignant pancreatic and peripancreatic diseases. In many tertiary referral centers, pancreaticoduodenectomy is now performed with complication rates less than 40% and with death rates of 5% or lower. As indications for pancreatectomy have expanded to include many benign or borderline lesions, this raises issues for long-term survivors (7,17,26,28,37).

Only about 10 percent of patients with pancreatic cancer are eligible for the procedure and pancreatic ductal adenocarcinoma is the most common epithelial exocrine pancreatic tumor, representing more than 85 percent of all malignant pancreatic tumors. In series of surgical resections, 80%-90% of tumors are located in the head of the gland (1,25,40).

Pancreatic cancer is the most common peripanillary adenocarcinoma. In different series of resected peripanillary cancers, pancreatic cancers accounted for approximately 60%, ampulla of Vater and distal bile cancers accounted for 10% to 20% each, and duodenal cancers accounted for 3% to 7%. Riall et al. found that 65% of 5-year survivors survived 5 more years, bringing them to the 10-year postresection landmark (31,40,41).

In chronic pancreatitis, pancreatic surgery is indicated when patients have untreated pain (12,15,18,24). Hereditary form of chronic pancreatitis represents 5%-10% of those affected and is also an important aetiological feature in pancreatic cancer (1,9,11,21,36,38).

It is known that even partial pancreatic resections can result in impairment of endocrine and exocrine pancreatic function.

Exocrine pancreatic insufficiency (EPI) is caused by inadequate or defective secretion of enzymes (1,14,28). The severity of postoperative EPI have functional and organic causes and varies with the extent of the resection, the functional capacity of the remaining gland and the changes in intestinal physiology (23,29,32,33).
A long-term study with a 14 year follow-up shows that 80% of patients with chronic pancreatitis have exocrine insufficiency as a late complication of the surgery\(^{(35)}\).

Once patients are diagnosed with EPI, the pancreatic enzyme replacement is the standard treatment, regardless of the etiology of failure. Several authors show that pancreatic enzyme replacement after a resection improves absorption of nutrients, the quality of life and nutritional status of patients\(^{(15,16,30,32,39)}\).

Patients with chronic pancreatitis may have worse EPI than others that underwent pancreatectomy. It is known that 32%-41% of patients with chronic pancreatitis present with malabsorptive symptoms prior to surgical intervention\(^{(22)}\). After additional loss of the pancreatic tissue, it can be expected that EPI will worsen and these patients will need higher doses of pancreatic enzyme supplementation\(^{(4)}\).

What is not clear yet, is if the long term remaining pancreatic exocrine function after partial pancreatic resection is different in patients with or without previous chronic pancreatitis. Nordback and Neoptolemos have shown that enzyme replacement begins immediately after pancreatic resection, the surgeon’s discretion, without examinations, according to the location and area of resection. Inadequate enzyme replacement doses can result in unnecessary costs\(^{(15,27)}\). Furthermore, several authors have demonstrated that post resection pancreatic enzyme replacement improves absorption of nutrients and thus the quality of life and nutritional status of patients\(^{(15,16,30,39)}\).

The aim of this study is to compare the amount and cost of enzyme replacement therapy in these patients.

**METHODS**

A tranversal observational study of patients submitted to pancreaticoduodenectomy (PDT) or gastroduodenopancreatectomy (GDT), carried out through the revision of the medical records of patients who were attended at the clinic of the Department of Gastrointestinal Surgery at Hospital das Clínicas, Universidade de São Paulo, Brasil. Data were collected in the first half 2015. The study was approved by the local Ethics Committee.

The inclusion criteria were: age \(\geq 18\), with at least 6 months follow up after pancreatectomy and under enzyme replacement therapy.

The variables age, gender, date of surgery, weight, height and lipase units consumed per day were collected from the medical records. We sought to identify the dose adjustment criteria, through the medical management recorded in medical records.

Patients were divided in two groups considering the pancreatic reconstruction indication: tumor or chronic pancreatitis.

The cost of enzyme replacement therapy was calculated based on the amount of lipase units consumed per day and the cost of Creon® capsules (10,000 and 25,000) reported by the Pharmacy Division of the Hospital. The conversion of the actual dollar value was accomplished by using the dollar value of the period, US$ 3.20.

Variables were compared using T-student test for independent averages. For this study, \(P<0.05\) was adopted as statistically significant. To calculate the \(P\) value for gender the Fischer test was used, so the \(P\) value represents the gender and not male/ female separately. To calculate the \(P\) value for age (median) the Wilcoxon test was used.

**RESULTS**

A total of 77 patients fit the inclusion criteria and they all were included in this study: 67.5% tumor, 32.5% chronic pancreatitis; 51.9% male, 48.1% female; the median age was 66.8 years (range 25-89). The average follow up time was 154 ± 81 months, body mass index (BMI) was 23.67 ± 4.20 kg/m\(^2\) (Table 1).

The ‘tumor’ group is composed of 52 patients; 38.5% were male; 61.5% female; median age 72.2 years (35-89 years). Average time postoperatively 154 ± 75 months, BMI 24.30 ± 4.77 kg/m\(^2\) (Table 1).

The ‘chronic pancreatitis’ group consists of 25 patients; 80% were male; 20% female; median age 59.6 years (26-76 years). Average time postoperatively 154 ± 94 months, BMI 22.37 ± 2.23 kg/m\(^2\) (Table 1).

It was observed a statistically significant difference between the variables \(P=0.0004697\), gender \((P=0.0007018)\) and BMI \((P=0.018)\).

The dose adjustment protocol is based on clinical symptoms reported by the patient and objective methods were not used.

Daily consumption of lipase was 85,000 ± 56,507 units/day; in tumor group 83365 ± 30626 units/day; 88400 in pancreatitis group ± 30609 units/day. The cost of enzyme replacement treatment was US$ 6881.63 ± 2334.04/year; US$ 6778.19 ± 2393.26/year in the tumor group; US$ 7096.78 ± 2356.17/year in pancreatitis group. There is no statistically significant difference between the daily lipase consumption between groups \((P=0.50)\) or the annual cost of replacement enzymes \((P=0.58)\) (Table 2).

| Variable                  | Tumor  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=52</td>
</tr>
<tr>
<td>Age 72.2</td>
<td>39.6</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male 20 (38.5%)</td>
<td>20 (80%)</td>
</tr>
<tr>
<td>Female 32 (61.5%)</td>
<td>5 (20%)</td>
</tr>
<tr>
<td>Postoperative (months)</td>
<td>154 ± 75</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>24.30 ± 4.77</td>
</tr>
</tbody>
</table>

**TABLE 1.** Demographic and clinic characterization of post pancreatectomy patients
Comparing the enzyme replacement therapy cost in post pancreatectomy patients due to pancreatic tumor and chronic pancreatitis

TABLE 2. Comparison of enzyme replacement therapy cost in patients post pancreatectomy due to tumor or chronic pancreatitis

<table>
<thead>
<tr>
<th>Variable</th>
<th>Tumor n=52</th>
<th>Chronic pancreatitis n=25</th>
<th>P value</th>
<th>Total n=77</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipase units/per day</td>
<td>83365 ± 30626</td>
<td>88400 ± 30609</td>
<td>0.50</td>
<td>85000 ± 56507</td>
</tr>
<tr>
<td>Enzyme replacement therapy cost/year (US$)</td>
<td>6778.19 ± 2359.26</td>
<td>7096.78 ± 2356.17</td>
<td>0.58</td>
<td>6881.63 ± 2354.04</td>
</tr>
</tbody>
</table>

DISCUSSION

The EPI causes poor digestion of food and poor absorption of nutrients, leading to weight loss, and steatorrhea, abdominal pain (fecal fat excretion ≥6g per day). It is also associated with deficiency of fat-soluble vitamins (A,D,E and K), magnesium, calcium and essential fatty acids, which cause symptoms such as night blindness and osteoporosis. The EPI is often associated with diabetes mellitus. Considering the complication rates of EPI, patients may have significant impairment of quality of life (QOL). Several studies show that the QOL has greater commitment postoperative immediate and medium period.

Our study found that there is no statistically significant difference between the cost of the enzyme replacement therapy in patients with and without chronic pancreatitis prior to pancreatectomy.

Previous studies suggested that the level of EPI is determined by clinical signs and that the pancreatic enzyme dose is adjusted according to the clinical response of patients. To optimize fat absorption, pancreatic enzyme replacement therapy requires and, therefore, should be adjusted in relation to disease severity and clinical response. Based on persistent signs and symptoms of malabsorption or adverse events or based on the subjective evaluation of the treating physician, the prescriber is routinely adjusting the enzyme doses. Currently there are no guidelines in clinical practice for monitoring the efficacy of enzyme replacement therapy and determining a need for dose adjustment.

The diagnosis of EPI by clinical signs (increased number of evacuations, weight loss, steatorrhea, flatulence) is not efficient, since they manifest themselves only when 90%-95% of the excretion of enzymes is compromised.

Mild to moderate EPI is often neglected or not sought and represents a major problem, since no optimization of the exocrine function at this stage can significantly undermine the general health.

The gold standard for diagnosing malabsorption of fat is the fat balance in the feces over 72 hours. To carry out this examination the patient should be submitted to a diet with control of fat content for 3 days, collect and store refrigerated all the evacuated volume and then forward it to the quantification of fat in the stool. All this makes the laborious routine procedure, unreliable, impractical, unpleasant and uncomfortable. Because of these difficulties this test is rarely used in clinical practice.

As an alternative to quantitative measurement of fat in stools, fecal elastase test (FE-1) was introduced as an indirect method, user-friendly, accurate and non-invasive assessment of pancreatic function. It is an examination of high cost and not always available throughout the health system.

In this study, the group who had surgical indication due to chronic pancreatitis is predominantly composed of men and is also a younger group than the ‘tumor’. Chronic pancreatitis is the result from the complex interactions of various environmental and genetic factors, yet, in most cases the disease is the result of chronic alcohol abuse. This can be explain why the group is predominantly made up of young men.

Despite the statistically different BMI in these groups, both are eutrophic. The BMI alone is not enough to determine the nutritional status of the patient. This population needs a detailed nutritional assessment once a poor nutritional status is one of indicators of EPI, since the loss of the exocrine function leads to poor absorption and hence weight loss, so we can infer that our patients with pancreatitis have a more severe exocrine insufficiency. Both groups have the same follow-up and pancreatic enzyme dose.

These controversial findings corroborate the need to stratify the degrees of insufficiency to better treat patients. Patients may be being over treated and consequently harmed, since among the side effects of using pancreatic enzymes are headache (6%), dizziness (6%), abdominal pain (9%), flatulence and constipation. Still, clinical studies show that Creon is well tolerated with very few adverse events related, regardless of patient age.

CONCLUSION

There are no studies in the literature that compare the cost of treating these patients. Therefore, this finding may contribute to new studies to prove that there is a need to stratify the degree of exocrine pancreatic insufficiency and improve methods of determining doses of pancreatic enzymes, in order to save public money and improve the quality of life of these patients.

In conclusion, the patients that underwent pancreatectomy due to tumor or chronic pancreatitis have similar after pancreatectomy with and without previous chronic pancreatitis.

Authors' contributions

RESUMO - Contexto: Dentre as complicações pós-operatórias tardias da pancreatologia, a presença ou ausência de pancreatite crônica previa à cirurgia pode influenciar o custo do tratamento. O objetivo deste estudo é comparar a dose necessária de enzimas pancreáticas e o custo do tratamento de reposição em pacientes pancreatiticos.

Métodos: Estudo transversal observacional. No primeiro semestre de 2015 pacientes acompanhados no ambulatório de cirurgia do aparelho digestivo do HC-FMUSP, submetidos a pancreatologia, foram incluídos nessa pesquisa. O estudo foi aprovado pelo Comitê de Ética. Os pacientes foram divididos em dois grupos, de acordo com a presença ou ausência de pancreatite crônica prévia à cirurgia pancreática. Para este estudo, P<0,05 foi considerado como estatisticamente significativo.

Resultados: O custo anual do tratamento foi R$ 2194,18 ± 729,39; R$ 2118,18 ± 731,02 em pacientes sem pancreatite crônica e R$ 2217,74 ± 736,30 em pacientes com pancreatite crônica. Conclusão: Não houve diferença estatisticamente significativa no custo do tratamento de reposição enzimática entre os pacientes pancreatiticos com ou sem pancreatite crônica prévia à indicação cirúrgica.

DESCRITORES: Pancreatite crônica. Terapia de reposição de enzimas. Pancreatite pancreática.